Европейский рынок острого коронарного синдрома – тенденции отрасли и прогноз до 2029 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Европейский рынок острого коронарного синдрома – тенденции отрасли и прогноз до 2029 года

  • Healthcare
  • Published Report
  • Mar 2022
  • Europe
  • 350 Pages
  • Количество таблиц: 64
  • Количество рисунков: 35

Европейский рынок острого коронарного синдрома по типу (инфаркт миокарда без подъема сегмента ST, инфаркт миокарда с подъемом сегмента ST и нестабильная стенокардия), диагностике (стресс-тест, анализы крови , визуализация и другие), лечению (лекарства и хирургия), конечному пользователю (больницы и клиники, диагностические центры, академические институты и другие) — тенденции отрасли и прогноз до 2029 года.

Европейский рынок острого коронарного синдрома

Анализ и понимание рынка острого коронарного синдрома в Европе

Ожидается, что рынок острого коронарного синдрома в Европе значительно вырастет в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 4,7% в прогнозируемый период с 2022 по 2029 год и, как ожидается, достигнет 4 915,11 млн долларов США к 2029 году. Основными факторами, способствующими росту рынка острого коронарного синдрома, являются рост распространенности хронических заболеваний, таких как ишемическая болезнь сердца, ишемическая болезнь сердца и сосудистые заболевания, рост гериатрического населения, широкий ассортимент продукции, предлагаемой участниками рынка, что приведет к росту рынка острого коронарного синдрома в будущем.

Европейский рынок острого коронарного синдрома

Европейский рынок острого коронарного синдрома

Острый коронарный синдром относится к группе заболеваний, при которых снижается приток крови к сердцу. Состояния, связанные с ОКС, включают инфаркт миокарда с подъемом сегмента ST (ИМСПST), инфаркт миокарда без подъема сегмента ST (ИМБПST) и нестабильную стенокардию. Это тип ишемической болезни сердца (ИБС), который является причиной одной трети всех смертей у людей старше 35 лет. Некоторые формы ИБС могут протекать бессимптомно, но ОКС всегда имеет симптоматику.

Острый коронарный синдром (ОКС) является проявлением ишемической болезни сердца (ИБС) и обычно является результатом разрыва бляшек в коронарных артериях (атеросклероза). Распространенными факторами риска заболевания являются курение, гипертония, диабет, гиперлипидемия, физическая неактивность, ожирение в семье и неправильное питание. Злоупотребление кокаином также может привести к вазоспазму. Семейный анамнез раннего инфаркта миокарда (55 лет) также является фактором высокого риска.

Отчет о рынке острого коронарного синдрома в Европе содержит подробную информацию о доле рынка, новых разработках, влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического обзора, наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.

Отчет Метрика

Подробности

Прогнозируемый период

2022-2029

Базовый год

2021

Исторические годы

2020 (Можно настроить на 2019 - 2014)

Количественные единицы

Доход в млн. долл. США, цены в долл. США

Охваченные сегменты

By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others)

Countries Covered

Germany, France, United Kingdom, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey & Rest of Europe

Market Players Covered

AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.

Europe Acute Coronary Syndrome Market Dynamics

Drivers

  • Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases

As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.

  • Growing Geriatric Population

The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in Europe& Asia-Pacific region, creates an opportunity for market growth in the forecast period.

  • Wide Range of Products Offered by Market Players

Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.

Opportunities

As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global acute coronary syndrome market in the forecast period.

Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.

The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.

This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Acute Coronary Syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In November 2021, Merck, announced the successful completion of the acquisition of Acceleron Pharma Inc. It is an important and strategic opportunity for the company to continue growing their cardiovascular portfolio and pipeline that builds on long and proud legacy in cardiovascular disease and further bolsters the company’s business development strategy fueled by Acceleron’s groundbreaking research.

Europe Acute Coronary Syndrome Market Scope

Europe acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Non-St-Elevation Myocardial Infarction
  • St-Elevation Myocardial Infarction
  • Unstable Angina

On the basis of type, the Europe acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.

Diagnosis

  • Stress Test
  • Blood Tests
  • Imaging
  • Others

On the basis of diagnosis, the Europe acute coronary syndrome market is segmented into stress test, blood test, imagining and others.

Treatment

  • Medication
  • Surgery

On the basis of treatment, the Europe acute coronary syndrome market is segmented into medication and surgery.

End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Academic Institutes
  • Others

Европейский рынок острого коронарного синдрома

On the basis of end user, the Europe acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.

Acute Coronary Syndrome Market Regional Analysis/Insights

Europe acute coronary syndrome market is further segmented into major countries including Germany, France, United Kingdom, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey & Rest of Europe.

Germany in Europe dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major players and well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Acute Coronary Syndrome Market Share Analysis

Europe acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acute coronary syndrome market.

Some of the prominent participants operating in the Europe acute coronary syndrome market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and others.

Research Methodology

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, анализ доли рынка компании, стандарты измерения, глобальный/региональный и анализ доли поставщиков. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ACUTE CORONARY SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 EUROPE ACUTE CORONARY SYNDROME MARKET: REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES, SUCH AS CORONARY ARTERY DISEASE, ISCHEMIC HEART DISEASE, AND VASCULAR DISEASES

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 WIDE RANGE OF PRODUCTS OFFERED BY MARKET PLAYERS

6.1.4 IMPROVING HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT POLICIES

6.2 RESTRAINTS

6.2.1 RISE IN COST OF THERAPEUTIC SURGERY

6.2.2 STRINGENT RULES & REGULATIONS

6.3 OPPORTUNITIES

6.3.1 SURGE IN TECHNOLOGICAL ADVANCEMENTS FOR CARDIOVASCULAR DISEASE

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 INCREASED REIMBURSEMENT POLICIES

6.3.4 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF ACCESSIBILITY OF SERVICES

6.4.2 LONG PROCESS OF APPROVAL BY REGULATORY BODIES

7 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TYPE

7.1 OVERVIEW

7.2 NON-ST- ELEVATION MYOCARDIAL INFARCTION

7.3 ST-ELEVATION MYOCARDIAL INFARCTION

7.4 UNSTABLE ANGINA

8 EUROPE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS

8.1 OVERVIEW

8.2 STRESS TEST

8.3 BLOOD TEST

8.4 IMAGING

8.5 OTHERS

9 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.3 SURGERY

10 EUROPE ACUTE CORONARY SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS AND CLINICS

10.3 DIAGNOSTIC CENTERS

10.4 ACADEMIC INSTITUTES

10.5 OTHERS

11 EUROPE ACUTE CORONARY SYNDROME MARKET, BY REGION

11.1 EUROPE

11.1.1 GERMANY

11.1.2 FRANCE

11.1.3 U.K.

11.1.4 ITALY

11.1.5 RUSSIA

11.1.6 SPAIN

11.1.7 TURKEY

11.1.8 NETHERLANDS

11.1.9 SWITZERLAND

11.1.10 BELGIUM

11.1.11 REST OF EUROPE

12 EUROPE ACUTE CORONARY SYNDROME MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 NOVARTIS AG

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.1.5.1 PRODUCT EXPANSION

14.1.5.2 COLLABRATION

14.2 ASTRA ZENECA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.2.5.1 ACQUISITION

14.3 AMGEN INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 SANOFI

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.4.5.1 ACQUISITION

14.5 BAXTER

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 DR. REDDY’S LABORATORIES LTD.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.6.4.1 ACQUISTION

14.7 PFIZER INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 MERCK & CO., INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.8.4.1 EVENT

14.8.4.2 ACQUISTION

14.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.9.3.1 PRODUCT APPROVAL

14.1 CSL

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.10.4.1 ACQUISITION

14.11 DAIICHI SANKYO COMPANY,LIMITED

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.11.4.1 PARTNERSHIP

14.12 JOHNSON & JOHNSON SERVICES, INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENT

14.12.4.1 ACQUISITION

14.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT

14.13.4.1 ACQUISITION

14.14 REGENERON PHARMACEUTICALS INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Список таблиц

TABLE 1 LIST OF RECENT PROGRESS OF 3D BIO PRINTING FOR CARDIAC TISSUE ENGINEERING-

TABLE 2 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 EUROPE NON-ST-ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ST—ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE UNSTABLE ANGINA IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 7 EUROPE STRESS TEST IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE BLOOD TEST IN ACUTE SYNDROME CORONARY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE IMAGING IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 EUROPE MEDICATION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE SURGERY IN ACUTE CORONARY SYNDROME MARKET, BY REGION 2020-2029 (USD MILLION)

TABLE 14 EUROPE ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 15 EUROPE HOSPITALS AND CLINICS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE DIAGNOSTIC CENTERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE ACADEMIC INSTITUTES IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE ACUTE CORONARY SYNDROME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 EUROPE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 22 EUROPE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 EUROPE ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 24 GERMANY ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 GERMANY ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 26 GERMANY ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 GERMANY ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 FRANCE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 FRANCE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 30 FRANCE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 FRANCE ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 U.K. ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 U.K. ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 34 U.K. ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 U.K. ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 ITALY ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 ITALY ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 38 ITALY ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 39 ITALY ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 RUSSIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 RUSSIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 42 RUSSIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 RUSSIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 SPAIN ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 SPAIN ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 46 SPAIN ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 SPAIN ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 TURKEY ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 TURKEY ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 50 TURKEY ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 TURKEY ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 NETHERLANDS ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 NETHERLANDS ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 54 NETHERLANDS ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 NETHERLANDS ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 SWITZERLAND ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 SWITZERLAND ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 58 SWITZERLAND ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 SWITZERLAND ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 BELGIUM ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 BELGIUM ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 62 BELGIUM ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 63 BELGIUM ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 REST OF EUROPE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

Список рисунков

FIGURE 1 EUROPE ACUTE CORONNARY SYNDROME MARKET: SEGMENTATION

FIGURE 2 EUROPE ACUTE CORONARY SYNDROME MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ACUTE CORONARY SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ACUTE CORONARY SYNDROME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE ACUTE CORONARY SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ACUTE CORONARY SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE ACUTE CORONARY SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE ACUTE CORONARY SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 EUROPE ACUTE CORONARY SYNDROME MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING PREVALENCE OF CORONARY ARTERY DISEASE, ISCHEMIC HEART AND VASCULAR DISEASE AS WELL AS GROWING GERIATRIC POPULATION IS DRIVING THE EUROPE ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE CORONARY SYNDROME MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ACUTE CORONARY SYNDROME MARKET

FIGURE 14 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2021

FIGURE 15 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2021

FIGURE 19 EUROPE ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)

FIGURE 20 EUROPE ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, CAGR (2022-2029)

FIGURE 21 EUROPE ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 22 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2021

FIGURE 23 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 24 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 25 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 EUROPE ACUTE CORONARY SYNDROME MARKET: BY END USER, 2021

FIGURE 27 EUROPE ACUTE CORONARY SYNDROME MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE ACUTE CORONARY SYNDROME MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 EUROPE ACUTE CORONARY SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 EUROPE ACUTE CORONARY SYNDROME MARKET: SNAPSHOT (2021)

FIGURE 31 EUROPE ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021)

FIGURE 32 EUROPE ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 EUROPE ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 EUROPE ACUTE CORONARY SYNDROME MARKET: BY TYPE (2022-2029)

FIGURE 35 EUROPE ACUTE CORONARY SYNDROME MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The Europe Acute Coronary Syndrome Market will be projected to grow at a CAGR of 4.7% during the forecast by 2029.
The Europe Acute Coronary Syndrome Market will be projected at USD 4,915.11 million during the forecast by 2029.
The major players operating in the Europe Acute Coronary Syndrome Market are AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.
The significant factors flourishing the growth of the Europe Acute Coronary Syndrome Market are Growing Geriatric Population and Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases.